Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Guy Melamed, Chief Financial Officer and Chief Operating Officer of Varonis Systems Inc (NASDAQ:VRNS), sold 51,889 shares of the company’s common stock on August 1, 2025. The transaction comes as Varonis, a $6.14 billion market cap company, maintains impressive gross profit margins of 81.46% and trades near its 52-week high of $60.58. The shares were sold at a weighted average price of $55.10, for a total transaction value of $2,859,083. Prices for the shares ranged from $55.01 to $55.24.
Following the transaction, Melamed directly owns 470,602 shares of Varonis Systems Inc.
The sale was executed under a Rule 10b5-1 trading plan.
In other recent news, Varonis Systems has reported strong second-quarter 2025 earnings, surpassing market expectations with an earnings per share (EPS) of $0.03 compared to the forecasted $0.01. The company’s revenue also exceeded predictions, reaching $152.2 million against an anticipated $148 million. This robust performance has led to a series of analyst upgrades. RBC Capital raised its price target for Varonis Systems to $64 from $58, maintaining an Outperform rating, highlighting the company’s 19% annual recurring revenue (ARR) growth. Needham also increased its price target to $70 from $60, maintaining a Buy rating, and noted the company’s successful SaaS migration and strong demand environment. Cantor Fitzgerald followed suit, raising its price target to $63 from $60, while keeping an Overweight rating, after Varonis exceeded consensus estimates in revenue, ARR, and free cash flow. These developments reflect confidence in Varonis Systems’ strategic direction and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.